We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies.

X

Latest Post

July 31, 2017

Growth in GLP-1 Drugs May Offer Improved Outcomes to People with Type II Diabetes

The rise in type 2 diabetes has sparked a variety of treatment options, including glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1s are a class of injected drugs (additional oral options are currently in development) that &ldquo;mimic the action of GLP-1 and increase the incretin effect in patients with type 2 diabetes, stimulating the release of insulin.&rdquo;<sup>1</sup> Commonly used when oral treatment alone is not enough, the benefits of GLP-1s include a reduction of glucagon and glycosylated haemoglobin (HbA1c), weight loss and a low risk of hypoglycemia.<sup>2</sup>
Aileen Kinsella

Aileen Kinsella

Director, Segment Marketing, Pharma

Previous Posts
SmartDose Platform with Daikyo Crystal Zenith cartridge, plunger and telescopic screw

May 15, 2017

SmartDose® Platform Honored as Finalist in the 2017 Medical Design Excellence Awards

Tiffany Burke

Tiffany Burke

Director, Global Communications

Nurse holding syringe and vial with patient

May 02, 2017

Safety Always Matters - Especially Patient Safety

Joanne Neizer

Joanne Neizer

Specialist, Technical Customer Service

Mixject

April 28, 2017

Future Readiness - Compliance with New USP Chapter <382>

Daniel Bantz

Daniel Bantz

Tech Manager, Packaging & Performance, Laboratory

Load more